snowdeal logo

archives archives

{bio,medical} informatics

Tuesday, April 10, 2001

bookmark: connotea :: ::digg ::furl ::reddit ::yahoo::

find related articles. powered by google. Financial Times Slow-acting medicine
""There has been no revolution in medicine in the past 25 years," says Arthur Levinson, chairman and chief executive of Genentech.''

"It should not have been this way. In theory, a greater understanding of the biology of disease should make it easier to design drugs."

""Those waiting for a so-called genomics revolution will be disappointed," argues Mr Levinson at Genentech.

"Sequencing of the human genome is a very important scientific development. But it's difficult to say what will come out of it," warns Mr Sharer at Amgen. "It takes 10 years to develop a new medicine, so don't expect any overnight results. The project provides a parts list of the cellular mechanism of the body but it doesn't explain how those parts work together. We are not on the cusp of a discontinuity."
find related articles. powered by google. Scientific Computing World IN PERSON: Dr Malcolm Weir, Chief Executive Officer of Inpharmatica
"If you were going to build a drug discovery company from scratch now, you'd start with informatics. The pharmaceutical industry has not yet had the sea change in productivity it requires. Information generated through each drug discovery project needs to be recycled and re-used, whereas usually data is not re-interpreted and reapplied to new projects. The attrition from gene to drug is currently much too high. If the car industry threw away many, many automobiles to get one that works, that wouldn't be acceptable."

redux [05.26.00]
find related articles. powered by google. Biospace Biotech Productivity: Myth or Method?
""The data suggest that the biotechnology industry used to be more productive than Big Pharma, but not any longer," said Rebecca Henderson, a professor at MIT's Sloan School of Management whose been studying the question for six years. "The public biotechs have declining productivity… and look as if they are running into the same problems as Big Pharma."

On every metric that Henderson has studied---number of scientific papers and patents per R&D dollar, cost per new drug--she found that biotech and Pharma productivity were quickly converging, and both were getting worse. After spending six years of studying the question, Henderson says she has found "no systematic evidence that small firms are more productive.""

find related articles. powered by google. Drug Discovery Online Where Next for Genomics?
"First came germ theory with antibiotics. Then came replacement theory with insulin and growth factors. Now the paradigm for drug development has shifted once again: We have entered the era of genomics-based medicine.

In less than a decade a new genomics industry has taken hold. Gemomics companies now ferret through miles of genetic code to identify the genetic causes of disease, select potential target genes, and help big pharma find the next blockbuster.

But the face of genomics—or at least its role in drug discovery—is about to change, due largely to its own success. “We’re knee deep in potential targets,” says Nicholas Dracopoli, executive director of pharmacogenomics with Bristol-Myers Squibb. “Prioritising the targets is the rate limiting step.”"

"Leaders in the genomics field, as in any other industry, will be companies that offer a value-added service. Large pharmaceutical companies agree on what that service should be: integration of all the genomics information available. With more information readily accessible, companies can easily decide on whether to continue investigating potential targets.

So the future of genomics companies may rest in their IT and software capabilities, a view held by Celera Genomics, a newcomer to genomics. “We are entering an era of ‘cyberpharmaceutical’ drug development,” says Samual Broder, executive VP and chief medical officer. “Pharmaceutical corporations will use genomic databases, and other relational databases involving gene expression, proteomics etc. as the foundation of their drug discovery pipelines. One of the immediate goals... is to produce appropriate databases and software to link biologic and genomic information.”"

[ rhetoric ]

Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.


[ search ]

[ outbound ]

biospace / genomeweb / bio-it world / scitechdaily / biomedcentral / the panda's thumb / / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /

eyeforpharma /

nsu / nyt science / bbc scitech / newshub / biology news net /

informatics review / stanford / bmj info in practice / bmj info in practice /

[ schwag ]

look snazzy and support the site at the same time by buying some snowdeal schwag !

[ et cetera ]

valid xhtml 1.0?

This site designed by
Eric C. Snowdeal III .
© 2000-2005